Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 12/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.32 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17061856 | 1.00 | SCN9A (0.45) | SCN9ACHRM2CHRM1CHRM3KMT2A | |
| SCHEMBL17061857 | 1.00 | SCN9A (0.45) | SCN9ACHRM2CHRM1CHRM3KMT2A | |
| SCHEMBL17069401 | 1.00 | SCN9A (0.45) | SCN9ACHRM2CHRM1CHRM3KMT2A | |
| SCHEMBL17062393 | 0.88 | SCN9A (0.49) | SCN9AGPR119SCN5ASCN7A | |
| SCHEMBL17062394 | 0.88 | SCN9A (0.49) | SCN9AGPR119SCN5ASCN7A | |
| SCHEMBL16771146 | 0.88 | SCN9A (0.49) | SCN9AGPR119SCN5ASCN7A | |
| SCHEMBL16758838 | 0.84 | SCN9A (0.40) | SCN9ADPP4SCN5ASCN7A | |
| SCHEMBL17061699 | 0.84 | SCN9A (0.67) | SCN9AOPRM1OPRD1SCN5ASCN7A | |
| SCHEMBL16771193 | 0.84 | SCN9A (0.67) | SCN9AOPRM1OPRD1SCN5ASCN7A | |
| SCHEMBL16771014 | 0.84 | SCN9A (0.67) | SCN9AOPRM1OPRD1SCN5ASCN7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | SCN9A 1605/4885CHRM2 439/4885CHRM1 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.